Buy, sell, hold: 12 stocks to watch out before Diwali glitters

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol BureauHere are a dozen stocks for your portfolio.WiproMacquarie maintains neutral rating and revised target price to Rs 495 per share from Rs 570 per share, expecting  dollar revenue growth rate to lag large cap Indian IT service companies for FY17.    Morgan Stanley is underweight on the stock with target price at Rs 460 per share stating that growth is weakest among large peers that may keep valuation low.           IDFC is neutral on the stock with target price at Rs 520 per share and  expects revenue/earnings CAGR of 6.2 percent/2 percent over FY16-18.  MindtreeMacquarie downgrades it to underperform with target price cut to Rs 400 per share from Rs 550 per share.  It says margin may remain soft due to low revenue growth and pricing pressure. It has also cut FY17-19 EPS by 15 percent and lower target multiple to 12x from 14x.             IDFC downgrades it to neutral with target  price at Rs 445 per share as commentary on order bookings and growth visibility a little tepid. It adds valuations may remain subdued until growth visibility returns.    Credit Suisse maintains underperform call with target price cut to Rs 450 per share from Rs 500 per share as  valuations are still not attractive despite underperformance.   Morgan Stanley is underweight rating on the stock with target price cut by 4 percent to Rs 435 per share.  It sees 14-17 percent downside risk to  consensus FY17-18 EPS estimates  with lower FY17-19 dollar revenue estimates  by 1-3 percent and EPS by up to 2 percent.  HCL Tech Deutsche Bank reiterates sell rating with target price at Rs 690 per share.  It values the company at discount to Infosys due to lopsided rev growth, margin headwinds.             IDFC maintains neutral cal with target price increased by 1.2 percent to Rs 850 per share hoping that  inorganic strategy should help  kickstart growth engine. It adds that pricing pressure leaves limited room for positive margin surprise and sees 8 percent earnings CAGR for FY16-18 despite low teen revenue growth.

Dr Reddy’s LabsCredit Suisse maintains underperform with target price at Rs 2750 per share as high FY18 estimates ignore risks to several key US products  and next 2-3 quarters are  key for wide range of FY18 estimate to converge.  It expects US sales to rise 3 percent QoQ due to Zegerid and Nitroglycerin launch . Oberoi RealtyJP Morgan is overweight with target price at Rs 370 per share as Worli project is now building up  in contribution to pre-sales . It expects strong traction  in earnings in FY18.

LIC Housing FinanceCLSA has upgraded it to outperform from sell with target price increased to Rs 660 per share from Rs 470 per share  encouraged by reining-in of  aggression in the lap segment .    

Cairn IndiaCLSA has a buy call with  target price at  Rs 260 per share.

BioconCiti raises target price to Rs 1170 per share from Rs 935 per share as  it remains to be India’s most leveraged play on global bio-similars opportunity. It has raised FY17/18 EPS by 1 percent each.

DB CorpIDFC has an outperform call on the stock with target price at Rs 451 per share expecting it to post a CAGR of 12.5 percent over FY16-18.

ACCCredit Suisse maintains neutral call with target unchanged at Rs 1400 per share as  it reported weak results due to sharp decline of 10 percent in volume. It has cut CY16/17 EPS by 15/3 percent to factor  in weak September 2016 earnings.

Morgan Stanley is underweight on the stock with  target at Rs 1746 per share as lower volume and higher cost  drive Q3 earnings miss.